Albers et al. 2023 (PRJNA789542)
General Details
| Title | Engineered tRNAs suppress nonsense mutations in cells and in vivo |
|---|---|
| Organism | |
| Number of Samples | 8 |
| Release Date | 2021/12/16 00:00 |
| Sequencing Types | |
| Protocol Details |
Study Links
| GWIPS-viz | Trips-Viz |
|---|---|
Repository Details
| SRA | SRP351123 |
|---|---|
| ENA | SRP351123 |
| GEO | GSE191048 |
| BioProject | PRJNA789542 |
Publication
| Title | |
|---|---|
| Authors | Albers S,Allen EC,Bharti N,Davyt M,Joshi D,Perez-Garcia CG,Santos L,Mukthavaram R,Delgado-Toscano MA,Molina B,Kuakini K,Alayyoubi M,Park KJ,Acharya G,Gonzalez JA,Sagi A,Birket SE,Tearney GJ,Rowe SM,Manfredi C,Hong JS,Tachikawa K,Karmali P,Matsuda D,Sorscher EJ,Chivukula P,Ignatova Z |
| Journal | Nature |
| Publication Date | 2023 Jun |
| Abstract | Nonsense mutations are the underlying cause of approximately 11% of all inherited genetic diseases 1 . Nonsense mutations convert a sense codon that is decoded by tRNA into a premature termination codon (PTC), resulting in an abrupt termination of translation. One strategy to suppress nonsense mutations is to use natural tRNAs with altered anticodons to base-pair to the newly emerged PTC and promote translation 2-7 . However, tRNA-based gene therapy has not yielded an optimal combination of clinical efficacy and safety and there is presently no treatment for individuals with nonsense mutations. Here we introduce a strategy based on altering native tRNAs into  efficient suppressor tRNAs (sup-tRNAs) by individually fine-tuning their sequence to the physico-chemical properties of the amino acid that they carry. Intravenous and intratracheal lipid nanoparticle (LNP) administration of sup-tRNA in mice restored the production of functional proteins with nonsense mutations. LNP-sup-tRNA formulations caused no discernible readthrough at endogenous native stop codons, as determined by ribosome profiling. At clinically important PTCs in the cystic fibrosis transmembrane conductance regulator gene (CFTR), the sup-tRNAs re-established expression and function in cell systems and patient-derived nasal epithelia and restored airway volume homeostasis. These results provide a framework for the development of tRNA-based therapies with a high molecular safety profile and high efficacy in targeted PTC suppression. © 2023. The Author(s). |
| PMC | PMC10284701 |
| PMID | 37258671 |
| DOI |
| Run Accession | Study Accession | Scientific Name | Cell Line | Library Type | Treatment | GWIPS-viz | Trips-Viz | Reads | BAM | BigWig (F) | BigWig (R) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRR17920633 | PRJNA789542 | Homo sapiens | immortalized bronchial epithelial cells | Ribo-Seq | untreated |  |
 |
 |
 |
|
|
||
| SRR17920634 | PRJNA789542 | Homo sapiens | immortalized bronchial epithelial cells | tRNA | |
|
|
|
|
|
|||
| SRR17248237 | PRJNA789542 | Mus musculus | Lung - whole organ | Ribo-Seq | untreated | |
|
|
|
|
|
||
| SRR17248236 | PRJNA789542 | Mus musculus | Lung - whole organ | tRNA | |
|
|
|
|
|
|||
| SRR17248235 | PRJNA789542 | Mus musculus | Lung - whole organ | tRNA | |
|
|
|
|
|
|||
| SRR17248234 | PRJNA789542 | Mus musculus | Liver - whole organ | Ribo-Seq | untreated | |
|
|
|
|
|
||
| SRR17248233 | PRJNA789542 | Mus musculus | Liver - whole organ | tRNA | |
|
|
|
|
|
|||
| SRR17248232 | PRJNA789542 | Mus musculus | Liver - whole organ | tRNA | |
|
|
|
|
|
|||
| Run Accession | Study Accession | Scientific Name | Cell Line | Library Type | Treatment | GWIPS-viz | Trips-Viz | Reads | BAM | BigWig (F) | BigWig (R) |
ⓘ For more Information on the columns shown here see: About